Market Closed -
Sao Paulo
12:19:55 2024-06-14 EDT
|
5-day change
|
1st Jan Change
|
32.98
BRL
|
-1.49%
|
|
-0.33%
|
+43.64%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,619
|
13,454
|
7,841
|
11,375
|
9,021
|
11,611
|
-
|
-
|
Enterprise Value (EV)
1 |
9,176
|
12,944
|
6,822
|
10,930
|
8,582
|
10,579
|
9,067
|
7,152
|
P/E ratio
|
-13.3
x
|
-24
x
|
-17.5
x
|
-16.1
x
|
-16.6
x
|
37.3
x
|
11.8
x
|
12
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
25.3
x
|
24.9
x
|
11.2
x
|
12.2
x
|
7.26
x
|
5.98
x
|
4.13
x
|
3.46
x
|
EV / Revenue
|
24.1
x
|
24
x
|
9.72
x
|
11.7
x
|
6.9
x
|
5.45
x
|
3.22
x
|
2.13
x
|
EV / EBITDA
|
-13.5
x
|
-24.1
x
|
-16.2
x
|
-22.1
x
|
-38.4
x
|
53.3
x
|
8.71
x
|
5.17
x
|
EV / FCF
|
-17.8
x
|
512
x
|
-14.2
x
|
-30.7
x
|
-14.9
x
|
-178
x
|
11.5
x
|
7.62
x
|
FCF Yield
|
-5.62%
|
0.2%
|
-7.06%
|
-3.26%
|
-6.72%
|
-0.56%
|
8.69%
|
13.1%
|
Price to Book
|
11.9
x
|
17.4
x
|
8.45
x
|
29.6
x
|
10.5
x
|
8.79
x
|
3.85
x
|
2.35
x
|
Nbr of stocks (in thousands)
|
74,543
|
78,913
|
87,077
|
87,783
|
93,547
|
94,524
|
-
|
-
|
Reference price
2 |
129.0
|
170.5
|
90.05
|
129.6
|
96.43
|
122.8
|
122.8
|
122.8
|
Announcement Date
|
20-02-26
|
21-03-01
|
22-03-01
|
23-02-28
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
380.8
|
540.1
|
701.9
|
933
|
1,243
|
1,941
|
2,812
|
3,359
|
EBITDA
1 |
-681.1
|
-537.3
|
-421.7
|
-494.3
|
-223.4
|
198.7
|
1,041
|
1,382
|
EBIT
1 |
-705.6
|
-564.2
|
-459.7
|
-536.2
|
-267.8
|
242.3
|
858.7
|
1,310
|
Operating Margin
|
-185.27%
|
-104.46%
|
-65.5%
|
-57.47%
|
-21.54%
|
12.48%
|
30.54%
|
38.99%
|
Earnings before Tax (EBT)
1 |
-713.9
|
-553.1
|
-418.9
|
-690
|
-520.1
|
250.2
|
917.8
|
1,366
|
Net income
1 |
-715.1
|
-554.1
|
-418.8
|
-703.5
|
-536
|
307
|
921
|
1,220
|
Net margin
|
-187.77%
|
-102.6%
|
-59.66%
|
-75.4%
|
-43.11%
|
15.82%
|
32.76%
|
36.32%
|
EPS
2 |
-9.710
|
-7.110
|
-5.150
|
-8.030
|
-5.800
|
3.289
|
10.45
|
10.26
|
Free Cash Flow
1 |
-516.1
|
25.26
|
-481.7
|
-356.2
|
-577.1
|
-59.5
|
787.6
|
938
|
FCF margin
|
-135.52%
|
4.68%
|
-68.62%
|
-38.17%
|
-46.42%
|
-3.07%
|
28.01%
|
27.92%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
75.62%
|
67.87%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
85.52%
|
76.88%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-26
|
21-03-01
|
22-03-01
|
23-02-28
|
24-02-28
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
201.5
|
210.8
|
233.5
|
230.3
|
258.4
|
253.5
|
261.2
|
331.8
|
396.8
|
413.5
|
384.8
|
511.7
|
609.6
|
609.7
|
667.7
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-105.8
|
-86.88
|
-211.1
|
-131.4
|
-106.8
|
-138.1
|
-133.5
|
-20.84
|
24.62
|
34.9
|
-14.68
|
68.59
|
151.9
|
157.9
|
174.5
|
Operating Margin
|
-52.52%
|
-41.21%
|
-90.43%
|
-57.04%
|
-41.34%
|
-54.47%
|
-51.11%
|
-6.28%
|
6.21%
|
8.44%
|
-3.81%
|
13.4%
|
24.92%
|
25.9%
|
26.14%
|
Earnings before Tax (EBT)
1 |
-121.9
|
-104.1
|
-228.1
|
-256.4
|
-101.3
|
-512.7
|
-14.58
|
-33.17
|
40.37
|
41.45
|
8.528
|
96.27
|
176.1
|
155.1
|
176.5
|
Net income
1 |
-122
|
-105.3
|
-231.5
|
-257.7
|
-109.2
|
-516.8
|
-23.94
|
-40.94
|
45.66
|
36.12
|
9.819
|
96.21
|
186.4
|
128
|
146.5
|
Net margin
|
-60.55%
|
-49.95%
|
-99.14%
|
-111.93%
|
-42.27%
|
-203.85%
|
-9.16%
|
-12.34%
|
11.51%
|
8.74%
|
2.55%
|
18.8%
|
30.58%
|
20.99%
|
21.94%
|
EPS
2 |
-1.420
|
-1.200
|
-2.650
|
-2.940
|
-1.240
|
-5.860
|
-0.2700
|
-0.4600
|
0.4700
|
0.3700
|
0.0886
|
1.049
|
1.936
|
2.016
|
2.280
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-03-01
|
22-05-04
|
22-08-02
|
22-11-02
|
23-02-28
|
23-05-02
|
23-08-02
|
23-11-01
|
24-02-28
|
24-05-01
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
443
|
510
|
1,019
|
445
|
438
|
1,032
|
2,545
|
4,460
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-516
|
25.3
|
-482
|
-356
|
-577
|
-59.5
|
788
|
938
|
ROE (net income / shareholders' equity)
|
-77.3%
|
-70.1%
|
-49.6%
|
-40.9%
|
-86.2%
|
34.1%
|
53.9%
|
46.2%
|
ROA (Net income/ Total Assets)
|
-41.3%
|
-23.1%
|
-13.7%
|
-8.55%
|
-1.86%
|
9.74%
|
16.1%
|
-
|
Assets
1 |
1,732
|
2,404
|
3,066
|
8,230
|
28,771
|
3,153
|
5,707
|
-
|
Book Value Per Share
2 |
10.90
|
9.770
|
10.70
|
4.380
|
9.170
|
14.00
|
31.90
|
52.20
|
Cash Flow per Share
2 |
-6.200
|
1.380
|
-5.450
|
-3.720
|
-5.420
|
2.540
|
13.60
|
-
|
Capex
1 |
59.6
|
82.2
|
38.5
|
30.8
|
76.1
|
54.1
|
47.6
|
45.6
|
Capex / Sales
|
15.66%
|
15.22%
|
5.48%
|
3.3%
|
6.12%
|
2.79%
|
1.69%
|
1.36%
|
Announcement Date
|
20-02-26
|
21-03-01
|
22-03-01
|
23-02-28
|
24-02-28
|
-
|
-
|
-
|
Last Close Price
122.8
USD Average target price
167.1
USD Spread / Average Target +36.02% Consensus |
1st Jan change
|
Capi.
|
---|
| +18.15% | 124B | | +18.02% | 112B | | +5.07% | 22.94B | | -12.75% | 22.22B | | -9.86% | 17.02B | | -14.97% | 16.88B | | -39.94% | 16.87B | | +2.80% | 13.63B | | +106.26% | 10.31B |
Bio Therapeutic Drugs
|